Store
The Worldwide Market for Mass Spectrometry in IVD Markets, 2026
Publication Date: September 18, 2026
Tags: Diagnostics, Diagnostics Market Research, Genetic Diseases, In Vitro Diagnostics (IVD), Infectious Diseases, IVD, Labs, Mass Spectrometry, Microbiology, Next-Generation Sequencing (NGS), Oncology, Oncology and Cancer
Pages: 233
SKU: 26-045KA
Mass spectrometry is transitioning from a specialized analytical technology into a mainstream clinical diagnostics platform, creating one of the most significant growth opportunities in laboratory medicine.
For much of its history, mass spectrometry (MS) was confined to research institutions, pharmaceutical laboratories, and specialized reference testing facilities. Its unmatched analytical sensitivity and specificity made it indispensable for complex testing, but high costs, technical complexity, and labor-intensive workflows limited broader clinical adoption. That dynamic is changing rapidly. Today, regulatory standardization, workflow automation, integrated IVD solutions, and growing investment from major industry players are accelerating the movement of mass spectrometry into routine clinical diagnostics.
The market opportunity is substantial. Over the next five years, the global mass spectrometry market is expected to nearly double in size, driven by expanding clinical adoption, increasing automation, growing use of artificial intelligence, and the continued shift of mass spectrometry from specialist laboratories into mainstream diagnostic workflows. While research applications remain important, the most significant long-term growth opportunity lies within clinical diagnostics, where mass spectrometry remains in the early stages of market penetration and substantial room for expansion remains.
Kalorama Information’s The Worldwide Market for Mass Spectrometry in IVD Markets, 2026 examines how mass spectrometry is reshaping clinical laboratory testing across applications including microbial identification, therapeutic drug monitoring, steroid and hormone analysis, vitamin D testing, newborn screening, toxicology, metabolomics, and emerging proteomic diagnostics. It explores the competitive advantages driving adoption over traditional immunoassay-based methods and assesses where mass spectrometry is likely to become a disruptive force in laboratory medicine.
Beyond current applications, The Worldwide Market for Mass Spectrometry in IVD Markets, 2026 analyzes the technological, regulatory, and commercial forces that will define the market over the next decade. These include the expansion of fully automated clinical workflows, increasing use of artificial intelligence for data interpretation and laboratory efficiency, continued miniaturization of instruments, the emergence of point-of-need testing, advances in mass spectrometry imaging and spatial biology, and the growing importance of high-throughput and single-cell analysis. Particular attention is given to automation not as a diagnostic trend alone, but as a critical response to the chronic workforce shortages facing clinical laboratories worldwide.
For executives, investors, and strategic planners, The Worldwide Market for Mass Spectrometry in IVD Markets, 2026 identifies where value creation is occurring across instruments, consumables, IVD kits, laboratory-developed tests, software, and workflow solutions. It evaluates the competitive positions of leading suppliers while examining acquisitions, partnerships, financings, and technology alliances that are reshaping the industry and influencing future market leadership.
For marketing, product management, and business development teams, the study provides insight into evolving customer needs, purchasing trends, adoption barriers, reimbursement dynamics, and the market narratives that are most effectively driving adoption as clinical mass spectrometry moves from a niche capability toward routine laboratory practice.
Global in scope, The Worldwide Market for Mass Spectrometry in IVD Markets, 2026 analyzes opportunities across North America, Europe, Japan, China, India, and other emerging markets. It also examines the evolving regulatory environment for laboratory-developed tests and IVD products, the impact of broader economic conditions, and the trends expected to influence investment, purchasing decisions, and competitive strategy through 2030.
The question is no longer whether mass spectrometry belongs in the clinical laboratory. The question is which companies will capture the value created as clinical mass spectrometry moves into the mainstream.
Chapter 1: Executive Summary
About Kalorama Information
Overview
History
Current Use of Mass Spectrometry
Scope and Methodology
Point of View
Market Overview
Future Prospects in the Mass Spectrometry Market
Miniaturization and Point-of-Need Analysis
Artificial Intelligence and Autonomous Automation
Clinical and Spatial Integration
High-Throughput Omics and Single-Cell Analysis
Chapter 2: Introduction to Mass Spectrometry
Background
Brief History of Mass Spectrometry
Ionization Techniques
Electrospray Ionization (ESI)
Matrix-Assisted Laser Desorption/Ionization (MALDI)
Atmospheric Pressure Chemical Ionization (APCI)
Atmospheric Pressure Photoionization (APPI)
Mass Analyzers
Quadrupole
Time-of-Flight (ToF)
Ion Trap
Ion Cyclotron Resonance
Hyphenated Techniques
GC/MS
LC/MS
TOF-MALDI
ICP-MS
CE/MS
Other Techniques
Tandem Mass Spectrometry
Shotgun Proteomics
Latest Developments and the Impact of AI
Trapped Ion Mobility Spectrometry-Mass Spectrometry (TIMS-MS)
High-Speed Hybrid Analyzers
High-Resolution Charge Detection Mass Spectrometry (CDMS)
AI-Driven Computational Mass Spectrometry & Real-Time Data Acquisition
Mass Spectrometry Market Segments
Clinical Laboratories
Oncology
Infectious Disease
Other Clinical Applications of Mass Spectrometry
Laboratory-Developed Tests (LDTs) for Mass Spectrometry
Historical FDA Regulation of LDTs
Current 2026 Status of FDA Regulations and Implications
European Regulatory Landscape
Regulation in Rest of World
In Vitro Diagnostics (IVDs)
Regulatory Environment
MS Instrument Regulatory Approval
Research Applications of Mass Spectrometry
Other Applications of Mass Spectrometry
Chapter 3: Mass Spectrometry Products and Manufacturers
Companies Marketing Mass Spectrometry Platforms and Related Products
- Table 3-1: Selected Companies Marketing Mass Spectrometers and/or Assays for the Clinical Laboratory [CE-marked and/or 510(k) cleared]
Pricing Trends
New Product Development Trends and AI
Integration with AI
Sales and Distribution Trends
Chapter 4: Market Drivers and Challenges in Mass Spectrometry
Market Drivers
Technological Advancements
Mass Spectrometry
Next Generation Sequencing
AI in LDT Development
Expanding Applications for MS and NGS
Mass Spectrometry
Next Generation Sequencing
Personalized Medicine
The Intersection of Personalized Medicine, MS and LDTs with AI
Companion Diagnostics
Global Health and Biosecurity
Rise of Benchtop and Portable MS Systems
Automation and Informatics Integration
Environmental and Food Safety Compliance
Market Challenges
Regulatory Changes
Conversion from CLIA Lab Services Offerings to IVD Kits
- Table 4-1: Selected FDA Approved/Cleared Laboratory-Developed Tests
Reimbursement
The Protecting Access to Medicare Act (PAMA)
Reduced Access to Investor Capital
Initial Public Offerings (IPOs) and Financings
- Table 4-2: Selected IPOs of Key Clinical Diagnostics and/or LDT Players, 2020-2026
Mergers and Acquisitions
- Table 4-3: Selected Acquisitions of or by Companies/Laboratories with LDTs, 2020-2026
Skilled Workforce Shortage
Supply Chain and Geopolitical Pressures
Semiconductor Shortages, AI Competition, and “Chipflation”
Strategic Implications for Clinical Laboratories
Chapter 5: Mass Spectrometry Market Analysis
Worldwide Mass Spectrometry Market
- Table 5-1: Global Market for Mass Spectrometry Instruments, Microbiology vs. Non-Microbiology Segments, 2025–2030 (US$ millions)
- Figure 5-1: Global Market for Mass Spectrometry Instruments, Microbiology vs. Non-Microbiology Segments, 2025–2030 (US$ millions)
- Table 5-2: Global Market for Mass Spectrometry Instruments by Segment, Share of Total, 2025 vs. 2030 (%) [Microbiology, Non-Microbiology]
- Figure 5-2: Global Market for Mass Spectrometry Instruments by Segment, Share of Total, 2025 vs. 2030 (%) [Microbiology, Non-Microbiology]
Mass Spectrometry Market by Technology
- Table 5-3: Global Market for Mass Spectrometry Instruments, by Technology, 2025–2030 (US$ millions) [FT/MS & Ion Trap, GC/MS, ICP-MS, LC/MS-MS, LC-TOF/Q-TOF, MALDI-TOF]
- Figure 5-3: Global Mass Spectrometry Instrument Market by Technology, 2025 and 2030 (US$ millions) [FT/MS & Ion Trap, GC/MS, ICP-MS, LC/MS-MS, LC-TOF/Q-TOF, MALDI-TOF]
- Figure 5-4: Mass Spectrometry Technologies, Market Size and Forecast CAGR, Size in 2025 vs. Growth to 2030 [FT/MS & Ion Trap, GC/MS, ICP-MS, LC/MS-MS, LC-TOF/Q-TOF, MALDI-TOF]
- Table 5-4: Global Market for Mass Spectrometry Instruments by Technology, Share of Total, 2025 vs. 2030 (%) [FT/MS & Ion Trap, GC/MS, ICP-MS, LC/MS-MS, LC-TOF/Q-TOF, MALDI-TOF]
- Figure 5-5: Global Mass Spectrometry Instrument Market Share, by Technology, 2025–2030 (%) [FT/MS & Ion Trap, GC/MS, ICP-MS, LC/MS-MS, LC-TOF/Q-TOF, MALDI-TOF]
Mass Spectrometry Market by Region
- Table 5-5: Global Market for Mass Spectrometry Instruments, by Region, 2025–2030 (US$ millions) [China, Europe, India, Japan, Latin America, US & Canada, Rest of World]
- Figure 5-6: Global Market for Mass Spectrometry Instruments by Region, 2025 vs. 2030 (US$ millions) [China, Europe, India, Japan, Latin America, US & Canada, Rest of World]
- Figure 5-7: Mass Spectrometry Regional Market Size and Forecast CAGR, Size in 2025 vs. Growth to 2030 [China, Europe, India, Japan, Latin America, US & Canada, Rest of World]
- Table 5-6: Global Mass Spectrometry Instrument Market Share, by Region, 2025–2030 (%) [China, Europe, India, Japan, Latin America, US & Canada, Rest of World]
- Figure 5-8: Global Mass Spectrometry Instrument Market Share, by Region, 2025–2030 (%) [China, Europe, India, Japan, Latin America, US & Canada, Rest of World]
Competitive Analysis
- Table 5-7: Total Estimated Mass Spectrometry Sales and Share of Key Mass Spectrometry Players, 2025 (US$ millions)
- Figure 5-9: Market Shares of Key Mass Spectrometry Players, 2025 (%)
Chapter 6: The Laboratory-Developed Test Market and Role of Mass Spectrometry
The Number of LDTs on the Market
Small versus Large Volume
LDT Services Market by Disease Segment
- Table 6-1: Laboratory-Developed Test Services Market, Major Clinical (Disease) Segments, 2025–2030, (US$ millions) [Genetic Testing, Infectious Disease, Oncology LDT Services Market]
Infectious Disease
Oncology
Genetic Testing
Other Laboratory-Developed Tests
LDT Services Market by Geography
- Table 6-2: Laboratory-Developed Test Services Market by Geographical Distribution, 2025–2030, (US$ millions)
LDT Products and Reagents by Market Segment (PCR, Mass Spectrometry, NGS. Microarrays and Other)
- Table 6-3: Worldwide Market for Products (Instruments and Consumables) Used by Clinical Laboratories for LDTs, 2025–2030 (US$ millions) [Mass Spectrometry, Next Generation Sequencing, Polymerase Chain Reaction, Other Assays (Microarrays, Other)]
Mass Spectrometry
- Figure 6-1: Mass Spectrometry Applications by Clinical Category, Share of Total Mass Spectrometry Applications, 2025 and 2030 (%) [Metabolomics, Microbiology, Newborn Screening, Proteomics, Steroid Hormones, Therapeutic Drug Monitoring, Toxicology, Vitamin D Metabolite Quantitation]
IVD Kits
- Table 6-4: Worldwide Market for Products IVD Kits Used by Clinical Laboratories, 2025–2030 (US$ millions) [Mass Spectrometry, Next Generation Sequencing, Polymerase Chain Reaction, Other Assays (Microarrays, Other)]
Geographic Distribution of Product and Reagents Used for LDT Market
- Table 6-5: Geographical Distribution of the Market for Products (Instruments and Consumables) Used by Clinical Laboratories for LDTs, 2025–2030 (US$ millions) [China, Europe, India, Japan, Latin America, U.S. & Canada, Rest of World]
Chapter 7: Impact of the Economy
Clinical Laboratory Testing
Mass Spectrometry
Current Economic Climate
Impact on Mass Spectrometry
Chapter 8: Company Profiles
908 Devices, Inc.
Company Overview
Financials
- Table 8-1: Revenues for 908 Devices, 2023–2025 (US$ millions)
Abbott Laboratories
Company Overview
Financials
- Table 8-2: Revenues for Abbott Laboratories, 2023–2025 (US$ billions)
Advion
Company Overview
Financials
Agena Bioscience
Company Overview
Financials
Agilent Technologies Inc.
Company Overview
Financials
- Table 8-3: Revenues for Agilent Technologies, 2023–2025 (US$ billions)
Aliri Bioanalysis
Company Overview
Financials
Beckman Coulter, Inc.
Company Overview
Financials
BGI
Company Overview
Financials
- Table 8-4: Revenues for BGI, 2023–2025 (US$ millions)
Biocrates Life Sciences, AG
Company Overview
Financials
Biodesix, Inc.
Company Overview
Financials
- Table 8-5: Revenues for Biodesix, 2023–2025 (US$ millions)
Biognosys AG
Company Overview
Financials
bioMérieux
Company Overview
Financials
- Table 8-6: Revenues for bioMérieux, 2023–2025 (US$ billions)
Bio-Rad Laboratories
Company Overview
Financials
- Table 8-7: Revenues for Bio-Rad, 2023–2025 (US$ billions)
Bruker Corporation
Company Overview
Financials
- Table 8-8: Revenues for Bruker, 2023–2025 (US$ billions)
CellCarta
Company Overview
Financials
Charles River Laboratories
Company Overview
Financials
- Table 8-9: Revenues for Charles River Laboratories, 2023–2025 (US$ billions)
Danaher Corporation
Company Overview
Financials
- Table 8-10: Revenues for Danaher, 2023–2025 (US$ billions)
JEOL, Ltd.
Company Overview
Financials
- Table 8-11: Revenues for JEOL, 2023–2025 (US$ billions)
Microsaic Systems plc
Company Overview
Financials
- Table 8-12: Revenues for Microsaic, 2023–2025 (US$ millions)
Mosaiques Diagnostics and Therapeutics AG
Company Overview
Financials
PerkinElmer, Inc./Revvity
Company Overview
Financials
- Table 8-13: Revenues for PerkinElmer/Revvity, 2023–2025 (US$ billions)
Proteome Sciences plc
Company Overview
Financials
- Table 8-14: Revenues for Proteome Sciences, 2023–2025 (US$ millions)
Roche
Company Overview
Financials
SCIEX Pte Ltd.
Company Overview
Financials
Sera Prognostics
Company Overview
Financials
Shimadzu Corp.
Company Overview
Financials
- Table 8-15: Revenues for Shimadzu Corp., 2023–2025 (US$ billions)
Standard BioTools
Company Overview
Financials
- Table 8-16: Revenues for Standard BioTools, 2023–2025 (US$ millions)
Thermo Fisher Scientific, Inc.
Company Overview
Financials
- Table 8-17: Revenues for Thermo Fisher Scientific, 2023–2025 (US$ billions)
Viome Life Sciences
Company Overview
Financials
Waters Corporation
Company Overview
Financials
- Table 8-18: Revenues for Waters Corp., 2023–2025 (US$ billions)
Related products
In Vitro Diagnostic (IVD) Test Procedure Volumes, 8th Edition
September 8, 2026
The world runs on roughly 150 billion diagnostic tests a year—and that number is climbing faster than the revenue behind it. IVD Test Procedure Volumes, 8th Edition quantifies that divergence with precision, tracking global procedure volumes segment by segment and region by region as the diagnostics industry completes its transition out of the pandemic era.…
Price range: $7,000.00 through $10,000.00
Worldwide Market for Clinical Laboratory Services, 11th Edition
July 31, 2026
Now in its 11th edition, Kalorama Information’s flagship review of clinical laboratory services gives decision-makers a rigorous, independent read on where diagnostic testing revenue sits today and where it is heading. Built on a 2025 base year, with historical data spanning 2020–2024 and forecasts running through 2030, the report is the reference stakeholders use to…
Price range: $5,950.00 through $8,500.00
Worldwide Market for Clinical Laboratory Services, 10th Edition
August 1, 2025
Worldwide Market for Clinical Laboratory Services, 10th Edition provides a definitive analysis of the global clinical lab services industry, offering critical insights into market size, growth drivers, testing types in demand, and competitive positioning from 2024 to 2029. This report is a key resource for stakeholders seeking to understand diagnostic service dynamics in the wake…
Price range: $5,600.00 through $8,000.00
